WuXi AppTec : INDICATIVE ANNOUNCEMENT REGARDING THE THIRD H SHARE CLASS MEETING
October 29, 2019 at 04:57 am EDT
Share
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.
WUXI APPTEC CO., LTD.*
無錫藥明康德新藥開發股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2359)
INDICATIVE ANNOUNCEMENT REGARDING
THE THIRD H SHARE CLASS MEETING
This announcement is made pursuant to the disclosure requirement under the articles of association (the "Articles of Association") of WuXi AppTec Co., Ltd.* (無錫藥明康德 新藥開發股份有限公司) (the "Company"). In this announcement, unless the context
otherwise requires, capitalised terms used herein shall have the same meanings as defined in the Company's circular (the "Circular") dated October 4, 2019.
In accordance with Article 83 of the Articles of Association, the Company may, on the basis of the written replies received twenty (20) days prior to the convention of the general meeting, calculate the number of voting shares represented by the Shareholders intending to attend the meeting. If the number of shares with voting rights represented by the Shareholders who have indicated that they would attend the general meeting is more than one-half (1/2) of the aggregate number of the shares with voting rights of the Company, the Company may hold a general meeting; if not, the Company shall, within five (5) days, inform the Shareholders once again in the form of announcement the proposed matters, date and place of the meeting, after which the Company may hold the general meeting. Details of the convening of the Third H Share Class Meeting are set out as follows:
DATE AND TIME OF THE THIRD H SHARE CLASS MEETING
The Third H Share Class Meeting will be held at 2:00 p.m. on Monday, November 18, 2019.
VENUE OF THE THIRD H SHARE CLASS MEETING
The Third H Share Class Meeting will be held Building No. 18, Lane 31, Yiwei Road, Pudong New Area, Shanghai, the PRC.
- 1 -
3. MATTERS TO BE CONSIDERED AT THE THIRD H SHARE CLASS MEETING
Please refer to the Circular and the notice of the Third H Share Class Meeting dated October 4, 2019.
For holders of H Shares of the Company, the form of proxy together with the power of attorney or other authority (if any) under which it is signed or a certified copy thereof, must be delivered to the Company's H Share Registrar, Tricor Investor Services Limited, at Level 54, Hopewell Centre, 183 Queen's Road East, Hong Kong, no later than 24 hours before the time appointed for the Third H Share Class Meeting. Completion and return of the form of proxy shall not preclude a H Shareholder of the Company from attending and voting in person at the Third H Share Class Meeting and, in such event, the instrument appointing a proxy shall be deemed to be revoked.
By Order of the Board
WuXi AppTec Co., Ltd.*
Dr. Ge Li
Chairman
Hong Kong, October 29, 2019
As of the date of this announcement, the Board of the Company comprises Dr. Ge Li, Mr. Edward Hu, Mr. Xiaozhong Liu, Mr. Zhaohui Zhang and Dr. Ning Zhao as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Dr. Jiangnan Cai, Ms. Yan Liu, Mr. Dai Feng, Dr. Hetong Lou and Mr. Xiaotong Zhang as independent non-executive Directors.
* For identification purposes only
- 2 -
Attachments
Original document
Permalink
Disclaimer
WuXi AppTec Co. Ltd. published this content on 29 October 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 October 2019 08:56:06 UTC
WuXi AppTec Co., Ltd. specializes in providing a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and biotech industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. Net sales break down by activity as follows:
- laboratory services (60.9%): small molecules discovery services, bioanalytical services, medical devices safety testing services, comprehensive manufacturing and testing services for cell and gene therapies, etc.;
- CMO and CDMO services (31.9%): development of manufacturing processes, production of advanced intermediates and active pharmaceutical ingredients, formulation development and dosage drug product manufacturing, for preclinical and clinical trials, new drug application, and commercial supply of chemical drugs, etc.;
- clinical research services (7.1%): project planning, clinical operation and monitoring and managements of phase I-IV clinical trials, medical device trials, etc.;
- other (0.1%).
Net sales are distributed geographically as follows: China (25.1%), Asia (4.1%), the United States (53.6%), Europe (16%) and other (1.2%) .
WUXI APPTEC CO., LTD. 
